Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Next Article in Journal
Impact of Oseltamivir and Diabetes Development
Previous Article in Journal
Examining Prenylated Xanthones as Potential Inhibitors Against Ketohexokinase C Isoform for the Treatment of Fructose-Driven Metabolic Disorders: An Integrated Computational Approach
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Review

Recent Advances in Peptide-Loaded PLGA Nanocarriers for Drug Delivery and Regenerative Medicine

Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2025, 18(1), 127; https://doi.org/10.3390/ph18010127 (registering DOI)
Submission received: 23 December 2024 / Revised: 13 January 2025 / Accepted: 15 January 2025 / Published: 18 January 2025

Abstract

Peptide-loaded poly(lactide-co-glycolide) (PLGA) nanocarriers represent a transformative approach to addressing the challenges of peptide-based therapies. These systems offer solutions to peptide instability, enzymatic degradation, and limited bioavailability by providing controlled release, targeted delivery, and improved stability. The versatility of PLGA nanocarriers extends across therapeutic domains, including cancer therapy, neurodegenerative diseases, vaccine development, and regenerative medicine. Innovations in polymer chemistry, surface functionalization, and advanced manufacturing techniques, such as microfluidics and electrospraying, have further enhanced the efficacy and scalability of these systems. This review highlights the key physicochemical properties, preparation strategies, and proven benefits of peptide-loaded PLGA systems, emphasizing their role in sustained drug release, immune activation, and tissue regeneration. Despite remarkable progress, challenges such as production scalability, cost, and regulatory hurdles remain.
Keywords: peptide therapeutics; PLGA nanocarriers; controlled drug release; regenerative medicine; targeted drug delivery peptide therapeutics; PLGA nanocarriers; controlled drug release; regenerative medicine; targeted drug delivery

Share and Cite

MDPI and ACS Style

Omidian, H.; Wilson, R.L.; Castejon, A.M. Recent Advances in Peptide-Loaded PLGA Nanocarriers for Drug Delivery and Regenerative Medicine. Pharmaceuticals 2025, 18, 127. https://doi.org/10.3390/ph18010127

AMA Style

Omidian H, Wilson RL, Castejon AM. Recent Advances in Peptide-Loaded PLGA Nanocarriers for Drug Delivery and Regenerative Medicine. Pharmaceuticals. 2025; 18(1):127. https://doi.org/10.3390/ph18010127

Chicago/Turabian Style

Omidian, Hossein, Renae L. Wilson, and Ana M. Castejon. 2025. "Recent Advances in Peptide-Loaded PLGA Nanocarriers for Drug Delivery and Regenerative Medicine" Pharmaceuticals 18, no. 1: 127. https://doi.org/10.3390/ph18010127

APA Style

Omidian, H., Wilson, R. L., & Castejon, A. M. (2025). Recent Advances in Peptide-Loaded PLGA Nanocarriers for Drug Delivery and Regenerative Medicine. Pharmaceuticals, 18(1), 127. https://doi.org/10.3390/ph18010127

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop